Century Therapeutics, Inc. (NASDAQ: IPSC) reported Q1 EPS of $0.89, $0.96 better than the analyst estimate of ($0.07). Revenue for the quarter came in at $109.16 million versus the consensus estimate of $19.94 million.

For earnings history and earnings-related data on Century Therapeutics, Inc. (IPSC) click here.